| abstract |
The invention provides antibodies that bind to prolactin receptors (PRLRs) and methods of using such antibodies. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention encompasses antibodies that bind to PRLR and block cellular signaling by prolactin vectors. In other embodiments, the invention encompasses antibodies that bind to PRLR but do not block cellular signaling by prolactin vectors. The antibody of the invention may be a fully human antibody. The invention includes anti-PRLR antibodies that bind to cytotoxic agents, radionuclides, or other moieties that are detrimental to cell growth or proliferation. The antibodies of the invention are useful in the treatment of a variety of cancers as well as other conditions associated with PRLR. The invention also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds to a Class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof binds to a cytotoxic agent. |